Cancer Care Ontario | Cancer Care Ontario

168 Results

Guidelines and Advice

First-line treatment of advanced-stage Hodgkin lymphoma

Status: Current
ID: ES 6-25

Oct 2024

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Guidelines and Advice

Endometrial Cancer Molecular Testing Recommendations Report

Status: Current
Version: 1

Nov 2024

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Updated

Aug 2025

Guidelines and Advice

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

Status: Current
ID: 7-13
Version: 2

Updated

Sep 2025

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Guidelines and Advice

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Status: Current
ID: 7-A-2022-1-17v3
Version: 3

Oct 2023

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Feb 2021

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

First-line treatment of advanced-stage Hodgkin lymphoma

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Endometrial Cancer Molecular Testing Recommendations Report

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Systemic Treatment Emergency Preparedness Guidance Document

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Pages